Research programme: anorectants - Abbott/Amgen

Drug Profile

Research programme: anorectants - Abbott/Amgen

Alternative Names: Anorectants research programme - Abbott/Amgen; Antiobesity agents research programme - Abbott/Amgen; Research programme: antiobesity agents - Abbott/Amgen

Latest Information Update: 11 Dec 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott GmbH & Co. KG; Tularik
  • Developer Tularik
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 11 Dec 2001 Discontinued-Preclinical for Obesity in USA (Unknown route)
  • 18 Jun 2001 Knoll notified Tularik that it is terminating the collaboration in obesity from October 31, 2001
  • 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top